The exorbitant cost of prescription drugs continues to be one of the biggest drains on the healthcare system. The Food and Drug Administration in June took steps to increase competition by posting a list of branded drugs that are not protected by patent and are not facing looming generic drug rivals. The agency will fast-track its review of generic drug applications.
